PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Terns Pharmaceuticals management to meet with Oppenheimer Promising Clinical Trials and Strong Financials Drive Buy Rating for Terns Pharmaceuticals PremiumThe FlyTerns Pharmaceuticals provides program updates Terns Pharmaceuticals sees cash runway into 2028 Terns Pharmaceuticals Appoints Andrew Gengos as CFO PremiumThe FlyNovartis CEO discusses search for obesity deals with WSJ Terns Pharmaceuticals price target raised to $20 from $17 at Oppenheimer Terns Pharmaceuticals Reports Promising Results in CML Trial